| 5.22 -0.13 (-2.43%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.37  |
1-year : | 9.85 |
| Resists | First : | 7.16 |
Second : | 8.43 |
| Pivot price | 6 |
|||
| Supports | First : | 5.11 |
Second : | 4.25 |
| MAs | MA(5) : | 5.42 |
MA(20) : | 6.26 |
| MA(100) : | 8.36 |
MA(250) : | 8.49 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 6.4 |
D(3) : | 9.5 |
| RSI | RSI(14): 22.8 |
|||
| 52-week | High : | 11.9 | Low : | 5.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EDIT ] has closed above bottom band by 15.9%. Bollinger Bands are 1.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.28 - 5.32 | 5.32 - 5.35 |
| Low: | 5.02 - 5.07 | 5.07 - 5.1 |
| Close: | 5.16 - 5.23 | 5.23 - 5.28 |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Tue, 23 Apr 2024
If You Had Bought Editas Medicine (NASDAQ:EDIT) Stock Three Years Ago, You Could Pocket A 65% Gain Today - Yahoo Movies Canada
Tue, 23 Apr 2024
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble ... - Simply Wall St
Mon, 22 Apr 2024
Editas to present gene editing advancements at ASGCT - Investing.com
Mon, 22 Apr 2024
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American ... - GlobeNewswire
Sun, 21 Apr 2024
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $15.00 Consensus Price Target from Analysts - MarketBeat
Tue, 12 Mar 2024
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 82 (M) |
| Shares Float | 76 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 80 (%) |
| Shares Short | 16,360 (K) |
| Shares Short P.Month | 13,520 (K) |
| EPS | -2.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.26 |
| Profit Margin | -196.2 % |
| Operating Margin | -40 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | -43.2 % |
| Qtrly Rev. Growth | 818.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.95 |
| EBITDA (p.s.) | -1.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -132 (M) |
| Levered Free Cash Flow | -88 (M) |
| PE Ratio | -2.59 |
| PEG Ratio | -1.3 |
| Price to Book value | 1.22 |
| Price to Sales | 5.49 |
| Price to Cash Flow | -3.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|